Wolfe Research started coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note published on Friday, Briefing.com Automated Import reports. The brokerage issued a peer perform rating on the stock.
Several other equities analysts have also recently issued reports on the company. Maxim Group restated a hold rating on shares of Arlington Asset Investment in a research note on Thursday, May 2nd. Wells Fargo & Co set a $17.00 price objective on Teva Pharmaceutical Industries and gave the stock a hold rating in a research note on Tuesday, May 28th. Barclays restated a hold rating on shares of Bank of Montreal in a research note on Tuesday, June 11th. Credit Suisse Group began coverage on LTC Properties in a research note on Wednesday, July 10th. They set an underperform rating and a $19.00 price objective on the stock. Finally, Sanford C. Bernstein set a €108.00 ($125.58) price objective on Merck KGaA and gave the stock a neutral rating in a research note on Tuesday, June 18th. Six research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries currently has a consensus rating of Hold and a consensus target price of $15.39.
TEVA stock opened at $7.91 on Friday. Teva Pharmaceutical Industries has a twelve month low of $7.66 and a twelve month high of $25.96. The company has a debt-to-equity ratio of 1.66, a current ratio of 0.96 and a quick ratio of 0.62. The firm has a market capitalization of $8.04 billion, a P/E ratio of 2.83, a P/E/G ratio of 0.95 and a beta of 1.62. The stock’s 50 day moving average is $8.87.
In related news, Director Sol J. Barer acquired 111,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were acquired at an average cost of $8.98 per share, for a total transaction of $996,780.00. Following the completion of the purchase, the director now directly owns 115,942 shares in the company, valued at $1,041,159.16. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Notaristefani Carlo De sold 16,070 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $11.42, for a total transaction of $183,519.40. Following the sale, the vice president now owns 49,659 shares in the company, valued at $567,105.78. The disclosure for this sale can be found here. 0.49% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in TEVA. G&S Capital LLC grew its holdings in Teva Pharmaceutical Industries by 99.4% during the second quarter. G&S Capital LLC now owns 4,012 shares of the company’s stock worth $37,000 after acquiring an additional 2,000 shares during the period. Lindbrook Capital LLC increased its stake in Teva Pharmaceutical Industries by 61.2% in the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock worth $39,000 after purchasing an additional 945 shares in the last quarter. NEXT Financial Group Inc increased its stake in Teva Pharmaceutical Industries by 384.8% in the 2nd quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock worth $39,000 after purchasing an additional 3,394 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new position in Teva Pharmaceutical Industries in the 1st quarter worth about $40,000. Finally, Edgemoor Investment Advisors Inc. purchased a new position in Teva Pharmaceutical Industries in the 1st quarter worth about $54,000. 65.05% of the stock is currently owned by hedge funds and other institutional investors.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: What is a portfolio manager?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.